Clinical Trials Logo

Neoplasms, Second Primary clinical trials

View clinical trials related to Neoplasms, Second Primary.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04714983 Suspended - Breast Cancer Clinical Trials

DNX-2440 for Resectable Colorectal Liver Metastasis

Start date: February 15, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery. Up to 18 patients will receive two sequential intra-tumoral injections of DNX-2440 into a metastatic liver tumor prior to surgery for liver resection, to evaluate safety and biological endpoints across 3 dose levels (dose escalation). Upon conclusion of the dose-escalation phase, the selected safe and biologically appropriate dose will be administered using the same schema for an additional 12 patients with colorectal cancer liver metastasis (expansion cohort) using established biologic endpoints.

NCT ID: NCT04115254 Suspended - Prostate Cancer Clinical Trials

Stereotactic Magnetic Resonance Guided Radiation Therapy

Start date: October 22, 2019
Phase: N/A
Study type: Interventional

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. - The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. - Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

NCT ID: NCT04108481 Suspended - Rectal Cancer Clinical Trials

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

iRE-C
Start date: October 5, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS).